menu
    • menu

    Company profile for Multitude Therapeutics

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Multitude Therapeutics (MTX) is a spinoff company from the Therapeutics division of Abmart to leverage its unparalleled target and antibody discovery capability for cancer immunotherapy. MTX focuses on developing antibody-drug conjugates (ADC), bispecific antibodies, and CAR-Ts for solid and hematological tumors. MTX’s therapeutic programs are based on novel cancer cell surface targets discovered by monoclonal antibody arra...
    Multitude Therapeutics (MTX) is a spinoff company from the Therapeutics division of Abmart to leverage its unparalleled target and antibody discovery capability for cancer immunotherapy. MTX focuses on developing antibody-drug conjugates (ADC), bispecific antibodies, and CAR-Ts for solid and hematological tumors. MTX’s therapeutic programs are based on novel cancer cell surface targets discovered by monoclonal antibody arrays (Human Membrane Proteome MabArrayTM or HMP-MabArrayTM) powered by the exceptional antibody discovery capabilities built at Abmart.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Multitude TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    3698 Haven Avenue, Suite A Redwood City, CA 94063
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.multitudetherapeutics.info/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Multitude’s AMT-253 Shows Early Efficacy in Solid Tumors at ESMO
    Multitude’s AMT-253 Shows Early Efficacy in Solid Tumors at ESMO

    19 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/multitude-therapeutics-announces-encouraging-interim-phase-iii-results-from-ongoing-first-in-human-study-evaluating-its-muc18-directed-antibody-drug-conjugate-amt-253-in-melanoma-and-other-advanced-solid-tumors-at-the-2025-esmo-302588336.html

    PR NEWSWIRE
    19 Oct 2025
    Share Share
    Multitude Therapeutics Reveals Positive Phase I/II Data
    Multitude Therapeutics Reveals Positive Phase I/II Data

    17 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/multitude-therapeutics-announces-promising-interim-phase-iii-results-from-the-ongoing-first-in-human-study-evaluating-its-cd44v9-directed-antibody-drug-conjugate-amt-116-in-heavily-pretreated-egfr-wild-type-non-small-cell-lung--302587390.html

    PR NEWSWIRE
    17 Oct 2025
    Share Share
    Multitude & Adcendo signed a licensing agreement for
    Multitude & Adcendo signed a licensing agreement for

    06 Sep 2024

    // PRESS RELEASE

    https://www.chemexpress.com/newsletter/Multitude-License

    PRESS RELEASE
    06 Sep 2024
    Share Share
    Adcendo And Multitude Therapeutics Partner On First-In-Class ADC
    Adcendo And Multitude Therapeutics Partner On First-In-Class ADC

    20 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/adcendo-aps-and-multitude-therapeutics-inc-announce-global-development-and-commercialization-agreement-on-first-in-class-adc-drug-candidate-targeting-tissue-factor-302225429.html

    PR NEWSWIRE
    20 Aug 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search